Press release
Investigation announced for Investors in shares of Cabaletta Bio, Inc. (NASDAQ: CABA) over potential Wrongdoing
An investigation on behalf of current long term investors in Cabaletta Bio, Inc. (NASDAQ: CABA) shares.
Investors who are current long term investors in Cabaletta Bio, Inc. (NASDAQ: CABA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ: CABA stocks follows a lawsuit filed against Cabaletta Bio, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: CABA stocks, concerns whether certain Cabaletta Bio, Inc. directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the Eastern District of Pennsylvania the plaintiff alleges that between October 24, 2019 and December 13, 2021, the Offering Documents and Defendants made false and/or misleading statements and/or failed to disclose that top-line data of the Phase 1 Clinical Trial indicated that DSG3-CAART had, among other things, worsened certain participants' disease activity scores and necessitated additional systemic medication to improve disease activity after DSG3-CAART infusion, that accordingly, DSG3-CAART was not as effective as the Company had represented to investors, that therefore, the Company had overstated DSG3-CAART's clinical and/or commercial prospects, and that as a result, the Company's public statements were materially false and misleading at all relevant times.
Those who purchased shares of Cabaletta Bio, Inc. (NASDAQ: CABA) have certain options and should contact the Shareholders Foundation.
Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of Cabaletta Bio, Inc. (NASDAQ: CABA) over potential Wrongdoing here
News-ID: 2649299 • Views: …
More Releases from Shareholders Foundation
Lawsuit filed for Investors in Charge Enterprises, Inc. (formerly NASDAQ: CRGE) …
An investor, who purchased shares of Charge Enterprises, Inc. (formerly NASDAQ: CRGE), filed a lawsuit over alleged violations of Federal Securities Laws by the former CEO and CFO of Charge Enterprises, Inc in connection with certain allegedly false and misleading statements made between December 15, 2021 and February 28, 2024.
Investors who purchased shares of Charge Enterprises, Inc. (formerly NASDAQ: CRGE) between December 15, 2021 and February 28, 2024, and continue…
Deadline on June 10th coming up in Lawsuit for Investors in shares of Ocugen, In …
A deadline is coming up on June 10, 2024 in the lawsuit filed for certain investors of Ocugen, Inc. (NASDAQ: OCGN) over alleged securities laws violations by Ocugen, Inc.
Investors who purchased shares of Ocugen, Inc. (NASDAQ: OCGN ) have certain options and there are strict and short deadlines running. Deadline: June 10, 2024. NASDAQ: OCGN stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to…
Investigation announced for Investors in FMC Corporation (NYSE: FMC) over potent …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of FMC Corporation.
Investors who are current long term investors in FMC Corporation (NYSE: FMC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NYSE: FMC stocks follows a lawsuit filed against FMC Corporation over…
Investigation announced for Long-Term Investors who lost money with Advance Auto …
An investigation was announced for long-term investors in shares of Advance Auto Parts, Inc. (NYSE: AAP) concerning potential breaches of fiduciary duties by certain directors of Advance Auto Parts, Inc.
Investors who are current long term investors in Advance Auto Parts, Inc. (NYSE: AAP) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long…
More Releases for Cabaletta
Myasthenia Gravis - Drug Pipeline Landscape, 2022
Myasthenia gravis is a chronic autoimmune neuromuscular condition that causes muscle weakness and severe fatigue. It causes weakness in the skeletal muscles, which are the muscles your body uses for movement. Myasthenia gravis is caused by a breakdown in the normal communication between nerves and muscles.
Healthcare professional checks neurological health by testing reflexes, muscle strength, muscle tone etc. Ice pack test, antibody tests, imaging scans and electromyogram can also be…
Myasthenia Gravis Pipeline Assessment | Insights into the Current Therapies, Eme …
"Myasthenia Gravis Pipeline Insight, 2022" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myasthenia Gravis Therapeutics Market.
The report provides a detailed description of the drug, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products…
Deadline in Lawsuit for Investors in Cabaletta Bio, Inc. (NASDAQ: CABA) coming u …
A deadline is coming up on April 29, 2022 in the lawsuit filed for certain investors of Cabaletta Bio, Inc. (NASDAQ: CABA) over alleged securities laws violations by Cabaletta Bio, Inc.
Investors who purchased shares of Cabaletta Bio, Inc. (NASDAQ: CABA) have certain options and there are strict and short deadlines running. Deadline: April 29, 2022 . NASDAQ: CABA stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
Attention NASDAQ: CABA Investors: Lawsuit filed against Cabaletta Bio, Inc.
An investor, who purchased shares of Cabaletta Bio, Inc. (NASDAQ: CABA), filed a lawsuit over alleged Securities Laws violations by Cabaletta Bio, Inc. in connection with certain allegedly false and misleading statements made in connection with the Company's initial public offering conducted on or about October 24, 2019 (the "IPO" or "Offering") and between October 24, 2019 and December 13, 2021.
Investors who purchased shares of Cabaletta Bio, Inc. (NASDAQ: CABA)…
Global Acute Lymphoblastic Leukemia Market Trends, Size, Competitive Analysis an …
Acute lymphoblastic/lymphocytic leukemia is one of the most common type of cancers that mainly affects children. There are two types of acute lymphocytic leukemia; B-cell type and T-cell type, that can be treated by radiation therapy, chemotherapy, targeted therapy, and others. The global acute lymphocytic leukemia market is expected to witness considerable growth during the forecast period. Increasing prevalence of acute lymphoblastic leukemia is encouraging the players in the market…
Global Artificial T-cell Receptors Market Size, Industry Trends, Share and Forec …
Artificial T-cell receptors provide enhanced ability to T-cells for targeting a specific protein. These receptors are often called as Chimeric Antigen Receptor (CAR) or Chimeric T-Cell Receptor which are bound to surface of T-cells and serve the purpose of alerting immune systems about the impending virus attack. The artificial T-cell receptors market is expected to grow at an impressive growth rate over the forecast period. A major factor that augments…
